Senator Cranks Up Pressure on Keystone KASH Over Its Alleged Quick‑Drink Test

When the talk of a handheld device that could spot a driver’s blood‑alcohol level in under a minute first hit Capitol Hill, a few eyebrows went up. The buzz was all about Keystone KASH – a little‑known startup that says it’s got a breakthrough test that’s faster, cheaper, and more accurate than anything on the market today.

But fast‑talk isn’t enough for Senator Maria Rivera (D‑CO). In a press conference last Tuesday, she pulled the plug on the optimism and asked a simple, if uncomfortable, question: Can you actually prove it works? The senator’s tone was unmistakably firm, but not hostile – she’s “just looking out for the American taxpayer and the safety of our roads,” she said, “and that means we need hard data, not hopeful headlines.”

Keystone KASH, founded three years ago by a pair of chemical‑engineering PhDs, claims its breath‑based assay can deliver results in 45 seconds, a big leap from the five‑minute lab tests most law‑enforcement agencies still rely on. The company argues that this speed could make it feasible for roadside checkpoints, schools, and even workplaces to screen for alcohol impairment in real‑time.

That sounds promising – until you dig into the fine print. The startup’s white paper, released earlier this year, cites a 96‑percent accuracy rate, but the study was conducted on a sample of just 120 volunteers, most of whom were recruited from the researchers’ own university. No independent third‑party verification has been released, and the device has yet to undergo the rigorous FDA clearance process.

“We’re not saying the technology is perfect,” admitted Dr. Alan Greene, Keystone KASH’s co‑founder, during a brief interview. “We’re still in the validation phase. What we can say is the early data is encouraging, and we’re working with partners to expand the testing pool.” He added that a larger, multi‑site trial is slated for later this year, but gave no concrete timeline.

Senator Rivera’s office seized on that ambiguity. In a statement issued after the press briefing, her staff wrote, “While innovation is welcome, any product that could affect public safety must be subject to transparent, peer‑reviewed evidence. We will not allocate federal funds or endorse a technology until it meets those standards.” The statement also hinted that a hearing could be scheduled before the Senate Commerce Committee to examine the claims in depth.

The political stakes are higher than just a lab report. If Keystone KASH’s device passes scrutiny, it could unlock a cascade of federal contracts – from the Department of Transportation’s pilot programs to the National Highway Traffic Safety Administration’s “Safer Roads” initiative. Those contracts are worth millions, and they could also pave the way for private‑sector roll‑outs, potentially reshaping how alcohol impairment is monitored nationwide.

Critics argue that the senator’s push may be more about optics than substance. A few industry analysts note that the regulatory environment for point‑of‑care diagnostic tools is already cluttered, and adding another player could dilute resources. Yet supporters counter that the lack of competition has kept prices high, and a breakthrough could drive costs down for law‑enforcement agencies strapped for budget.

Meanwhile, families of victims of drunk‑driving accidents have voiced cautious optimism. “If there’s a way to catch people before they get behind the wheel, we’re all for it,” said Linda Marsh, whose brother was killed in a crash three years ago. “But we need to be sure it works – no half‑measures.”

So where does that leave Keystone KASH? For now, the company is scrambling to secure an independent lab to replicate its findings, a move that could either cement its credibility or expose flaws. Senator Rivera, for her part, says she’ll keep a close eye on the process, promising to “shine a light on any shortcuts or oversights.” The next few months could determine whether a promising idea becomes a nationwide safety tool – or a cautionary tale about hype outpacing hard data.